
"Paxlovid: Overcoming Hesitations in COVID Prevention"
Paxlovid, a combination of nirmatrelvir and ritonavir, can reduce the risk of severe COVID-19 symptoms and hospitalizations, but only 15% of eligible individuals have taken it. It should be started within the first five days of symptoms and is for high-risk patients aged 12 and older. Some doctors may not prescribe it due to shortages, unfamiliarity, and concerns about drug interactions. Side effects include temporary nausea and altered taste, and there's conflicting evidence on its effect on long COVID. It's important to consult a healthcare provider if considering Paxlovid and to continue preventive measures such as handwashing and vaccination.



